Original Research
Published on 18 Feb 2019
Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
in Pharmacology of Ion Channels and Channelopathies
Frontiers in Pharmacology
doi 10.3389/fphar.2019.00076
- 3,800 views
- 15 citations
